Brietta Forbes, MD
Pulmonary Disease · Overland Park, KSNPI 1154769115
Payments from drug & device makers
What this record shows
This record is dominated by education: $6,305 of the $10,187 with a category attached, or 61.9%. Intuitive Surgical accounts for 82.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $7,464 and has fallen 85.3% since, to $1,096 in 2025.
Across 109 payments — averaging $93.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- AstraZeneca$492
- Boehringer Ingelheim$234
- Sanofi$194
- Actelion Pharmaceuticals US, Inc.$143
- Siemens Medical Solutions USA, Inc.$138
- plus $615 from 16 others
What the payments were for
- Travel & lodging$2,21422%
- Food & beverage$1,66816%
- Education$6,30562%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 21 | $8,371 |
| AstraZeneca | 14 | $492 |
| Boehringer Ingelheim | 20 | $234 |
| Sanofi | 10 | $194 |
| Actelion Pharmaceuticals US, Inc. | 6 | $143 |
| Siemens Medical Solutions USA, Inc. | 1 | $138 |
| Grifols USA, LLC | 6 | $97 |
| Insmed, Inc. | 5 | $81 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| GSK | 3 | $51 |
| Mylan Specialty L.p. | 3 | $45 |
| Inogen, Inc. | 5 | $40 |
| Amgen | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Johnson & Johnson | 2 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $17 |
| Novartis | 1 | $15 |
| Electromed, Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$6,000
- Da Vinci Surgical System$2,124
- BREZTRI$191
- TUDORZA PRESSAIR$191
- BEVESPI AEROSPHERE$191
- TEZSPIRE$191
- FASENRA$191
How this compares
$10,187 in reported general payments places this provider in the 80th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 117 | $101,769 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $54,092 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $35,690 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $25,365 |
| XareltoRivaroxaban | 15 | $12,419 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $9,675 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,467 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $1,962 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $1,909 |
| Mycophenolate Mofetil | 11 | $999 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 16 | $879 |
| Montelukast Sodium | 34 | $421 |
| Azithromycin | 48 | $362 |
| Fluticasone Propionate | 12 | $196 |
| Prednisone | 64 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $51 | $115,147189 claims |
| AstraZenecaBreztri Aerosphere | $492 | $101,769117 claims |
| Johnson & JohnsonXarelto | $21 | $12,41915 claims |
| Boehringer IngelheimStiolto Respimat | $234 | $9,67520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Overland Park
- Mitchell TenerOverland Park$6K
- Jason FieserOverland Park$6K
- James KaplanOverland Park$4K
- Daniel BalmacedaOverland Park$3K
- Trenton NauserOverland Park$1K
- John NelsonOverland Park$1K
- Christine CookOverland Park$1K
- Scott EveloffOverland Park$903
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.